|
1) Maruo T, Ohara N, Wang J, et al. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004; 10: 207-20
|
|
|
|
2) Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007; 87: 1399-412
|
|
|
|
|
|
3) Chwalisz K, Perez MC, DeManno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005; 26: 423-39
|
|
|
|
|
|
4) Chwalisz K, Elger W, Stickler T, et al. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod. 2005; 26: 1090-9
|
|
|
|
|
|
5) Chwalisz K, Garg R, Brenner R, et al. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol. 2006; 4 Suppl: S8
|
|
|
|
|
|
6) Shimomura Y, Matsuo H, Samoto T, et al. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab. 1998; 83: 2192-8
|
|
|
|
|
|
7) Matsuo H, Maruo T, Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab. 1997; 82: 293-9
|
|
|
|
|
|
8) Kurachi O, Matsuo H, Samoto T, et al. Tumor necrosis factor-α expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab. 2001; 86: 2275-80
|
|
|
|
|
|
9) Williams ARW, Critchley HOD, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007; 22: 1696-704
|
|
|
|
|
|
10) Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2006; 91: 1296-304
|
|
|
|
|
|
11) Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly (adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005; 90: 953-61
|
|
|
|
|
|
12) Wang J, Ohara N, Wang Z, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFβ3, and their receptors in cultured uterine leiomyoma cells. Hum Reprod. 2006; 21: 1869-77
|
|
|
|
|
|
13) Sasaki H, Ohara N, Xu Q, et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2007; 92: 616-23
|
|
|
|
|
|
14) Xu Q, Ohara N, Chen W, et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin, and their receptors in cultured human uterine leiomyoma cells through modulating the expression of progesterone receptor. Hum Reprod. 2006; 21: 2408-16
|
|
|
|
|